1/23/2009

Patients with mucosa-associated lymphoid tissue lymphoma and low-grade follicular lymphoma in conjunctiva exhibited an 83% complete response rate to Zevalin, Cell Therapeutics' radioimmunotherapy, during a front-line study. The results show that Zevalin could be a good alternative to current treatments, providing lower ocular toxicity and equal or better disease control, said the company's chief medical officer.

Full Story:
RTT News

Related Summaries